Related Experiment Video
Updated: Mar 24, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Steroid-Resistant Immune Thrombocytopenia With Severe Bleeding Successfully Managed Using Eltrombopag and
Abdul Hanan Farooq1, Muhammad Badar Khalid2, Ayesha Muneer3
1Acute Medicine, University Hospitals Bristol and Weston NHS Foundation Trust, Weston-super-Mare, GBR.
Abstract:
A 67-year-old man presented with severe mucocutaneous bleeding and profound thrombocytopenia with a platelet count of 6 × 10³ per microliter. Bone marrow examination showed preserved megakaryocytes, and secondary causes were excluded, confirming primary immune thrombocytopenia (ITP). Despite high-dose intravenous methylprednisolone followed by oral corticosteroids, platelet count remained 8 × 10³ per microliter. Two weeks after the presentation, azathioprine was initiated due to persistent severe thrombocytopenia, and eltrombopag was added. Response remained minimal. One month after the presentation, he was classified as having steroid-refractory disease. Azathioprine was discontinued, and mycophenolate mofetil was started. Platelet count rose steadily, reaching 88 × 10³ per microliter at discharge and normalizing to more than 150 × 10³ per microliter within two weeks, with complete resolution of bleeding. This case highlights the diagnostic challenges of ITP in older adults and supports combining thrombopoietin receptor agonists (TPO-RAs) with targeted immunosuppressive therapy in steroid-refractory disease.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Venous Thrombosis III: Interprofessional Care
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
